11119 studies found for:    NCI
Show Display Options
Download search resultsDownload the search results for:
NCI (11119 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Not yet recruiting Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer
Conditions: BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions: Drug: Atezolizumab;   Other: Laboratory Biomarker Analysis;   Drug: Veliparib
2 Not yet recruiting Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Conditions: Recurrent Bladder Urothelial Carcinoma;   Stage 0a Bladder Urothelial Carcinoma;   Stage 0is Bladder Urothelial Carcinoma;   Stage I Bladder Cancer With Carcinoma In Situ;   Stage I Bladder Urothelial Carcinoma
Interventions: Drug: Atezolizumab;   Other: Laboratory Biomarker Analysis
3 Not yet recruiting Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Dermal Neurofibroma
Conditions: Appearance Distress;   Bothered by Itching Skin;   Cafe Au Lait Spot;   Cutaneous Neurofibroma;   Disfigurement;   Dysplasia;   Neurofibromatosis Type 1;   NF1 Gene Mutation;   Optic Nerve Glioma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Selumetinib
4 Not yet recruiting Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   High Grade Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Atezolizumab;   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Quality-of-Life Assessment
5 Not yet recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bladder Adenocarcinoma;   Bronchioloalveolar Carcinoma;   Cervical Adenocarcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Endometrial Adenocarcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Skin Neoplasm;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
6 Not yet recruiting Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and MLL Gene Rearrangement
Conditions: Acute Leukemia of Ambiguous Lineage;   Childhood B Acute Lymphoblastic Leukemia;   Mixed Phenotype Acute Leukemia
Interventions: Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
7 Not yet recruiting Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: CNS 2a;   CNS 2b;   CNS 2c;   CNS1;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Myeloid Leukemia
Interventions: Drug: Cytarabine;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: WEE1 Inhibitor AZD1775
8 Not yet recruiting Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia
Conditions: Chronic Atrophic Gastritis;   Intestinal Metaplasia of Gastric Mucosa
Interventions: Drug: Curcumin;   Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment
9 Not yet recruiting Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
Conditions: Childhood Brain Stem Neoplasm;   Childhood Lymphoma;   Childhood Solid Neoplasm;   Pineal Region Neoplasm;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Visual Pathway Glioma;   Refractory Central Nervous System Neoplasm
Interventions: Drug: Entinostat;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
10 Not yet recruiting Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
Condition: Desmoplastic Melanoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Procedure: Therapeutic Conventional Surgery
11 Not yet recruiting Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma
Conditions: Stage III Hypopharyngeal Squamous Cell Carcinoma;   Stage III Laryngeal Squamous Cell Carcinoma;   Stage III Oral Cavity Squamous Cell Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Hypopharyngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Oral Cavity Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Hypopharyngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Oral Cavity Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma
Interventions: Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Radiation: Radiation Therapy
12 Recruiting Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Recurrent Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Drug: Crizotinib;   Other: Laboratory Biomarker Analysis;   Drug: Sunitinib Malate;   Drug: Volitinib
13 Not yet recruiting Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis
Conditions: Acute Pancreatitis;   Chronic Pancreatitis;   Recurrent Disease
Interventions: Other: Laboratory Biomarker Analysis;   Other: Placebo;   Other: Quality-of-Life Assessment;   Drug: Simvastatin
14 Recruiting Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
15 Recruiting Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
Condition: Ductal Breast Carcinoma In Situ
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Nelipepimut-S Plus GM-CSF Vaccine;   Biological: Sargramostim
16 Recruiting Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Conditions: Acute Adult T-Cell Leukemia/Lymphoma;   Adult T-Cell Leukemia/Lymphoma;   Chronic Adult T-Cell Leukemia/Lymphoma;   HTLV-1 Infection;   Lymphomatous Adult T-Cell Leukemia/Lymphoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Smoldering Adult T-Cell Leukemia/Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacogenomic Study
17 Recruiting Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Neuroendocrine Neoplasm;   Progesterone Receptor Negative;   Stage IIB Cervical Cancer;   Stage IIIA Cervical Cancer;   Stage IIIB Cervical Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Cervical Cancer;   Stage IV Gastric Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Small Cell Lung Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Drug: Ferumoxytol;   Other: Laboratory Biomarker Analysis;   Drug: Liposomal Irinotecan;   Procedure: Magnetic Resonance Imaging;   Drug: Veliparib
18 Not yet recruiting Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Conditions: High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Tumor;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: ATR Kinase Inhibitor VX-970;   Drug: Carboplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
19 Withdrawn Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer
Conditions: Adult Solid Neoplasm;   Estrogen Receptor Negative;   Fallopian Tube Serous Neoplasm;   HER2/Neu Negative;   Ovarian Serous Adenocarcinoma;   Ovarian Serous Tumor;   Primary Peritoneal Serous Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Drug: Hsp90 Inhibitor AT13387;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Talazoparib
20 Recruiting Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
Conditions: Breast Carcinoma;   Neuropathy
Intervention: Other: Laboratory Biomarker Analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years